Autolus Therapeutics cuts 13% of workforce to boost efficiency and reduce costs

5 articles · Updated · MarketWatch · Apr 29

The company, which had 752 full-time employees as of December 31, expects to complete the layoffs by the third quarter and will incur about $8 million in restructuring charges.
Autolus anticipates the workforce reduction will lower annual operating expenses by $15 million starting in 2027, affecting employees across all areas of the business.
The biopharmaceutical firm’s move reflects ongoing industry pressures to optimize operations and manage costs as it advances its commercial-stage activities.

How can Autolus double production after laying off nearly 100 employees?

With cash dwindling, are these layoffs a strategic pivot or a sign of distress?

Is the Inflation Reduction Act forcing biotech firms to sacrifice jobs for survival?

Will cost-cutting today jeopardize the pipeline of tomorrow's life-saving cell therapies?

As analysts split on the company's future, is Autolus a smart investment or a risky bet?